Smt. Kanuri Santhamma Center for Vitreo Retina Services, Hyderabad, Telangana, India.
Center for Ocular Regeneration, L V Prasad Eye Institute, Hyderabad, Telangana, India.
Indian J Ophthalmol. 2019 May;67(5):677-680. doi: 10.4103/ijo.IJO_1943_18.
This study describes a novel surgical technique of fibrin glue-assisted retinopexy for rhegmatogenous retinal detachment (GuARD) without oil or gas tamponade after pars plana vitrectomy (PPV).
This pilot clinical trial included five eyes of five patients with rhegmatogenous retinal detachments (RD). A complete PPV was done in all cases followed by fluid-air exchange, laser photocoagulation around the break/s, and application of 0.1-0.2 mL of fibrin glue. No air, long-acting gas or silicone oil was used subsequently. No specific postoperative positioning was prescribed. The primary outcome measure was efficacy of the procedure defined as successful anatomical retinal reattachment. Secondary outcome measures were postoperative improvement in best corrected visual acuity (BCVA) and complications.
The median age of patients was 55 (range: 36-61 years) years and median duration of symptoms was 15 (range: 7-60) days. All eyes were pseudophakic, four eyes had inferior and one eye had total RD. Successful retinal reattachment was achieved in all (100%) cases and was maintained at the end of 3-8 months of follow-up. The median BCVA improved from 20/100 preoperatively to 20/80 at 1-week and 20/50 at 1-month postoperatively. None of the eyes had any postoperative complications such as elevated intraocular pressures or unexpected inflammation.
The findings of this study suggest that GuARD is a promising technique for treatment of rhegmatogenous RD that may allow early visual recovery while avoiding the problems of gas or oil tamponade and obviating the need of postoperative positioning.
本研究描述了一种新的手术技术,即纤维蛋白胶辅助视网膜固定术(GuARD),用于在玻璃体切除术(PPV)后无需油或气体填充治疗孔源性视网膜脱离(RD)。
本试点临床试验包括 5 例 5 只眼的孔源性 RD 患者。所有病例均行完整的 PPV,随后进行液-气交换、裂孔周围激光光凝,并应用 0.1-0.2 毫升纤维蛋白胶。随后未使用空气、长效气体或硅油。未规定特定的术后体位。主要疗效指标定义为手术成功的解剖视网膜复位。次要疗效指标为术后最佳矫正视力(BCVA)的改善和并发症。
患者的中位年龄为 55 岁(范围:36-61 岁),中位症状持续时间为 15 天(范围:7-60 天)。所有眼均为人工晶状体眼,4 只眼为下方 RD,1 只眼为全 RD。所有病例(100%)均成功实现视网膜复位,并在 3-8 个月的随访期末得到维持。中位 BCVA 从术前的 20/100 提高到术后 1 周的 20/80 和 1 个月的 20/50。所有眼均无术后并发症,如眼压升高或意外炎症。
本研究结果表明,GuARD 是治疗孔源性 RD 的一种有前途的技术,它可以在避免气体或油填充的问题的同时,避免术后体位的需要,从而实现早期视力恢复。